Genmab (CPSE:GMAB) Valuation Check After Epcoritamab Trial Update And DARZALEX Royalty Momentum [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
Genmab (CPSE:GMAB) has drawn fresh attention after releasing Phase 3 EPCORE DLBCL-1 topline data for epcoritamab and reporting 2025 worldwide DARZALEX net trade sales of US$14.35b under its Johnson & Johnson license. The twin updates matter because they touch both sides of the Genmab story: current royalty cash flows from partnered drugs, and the longer term value investors may see in its late stage oncology pipeline. See our latest analysis for Genmab. The recent trial update and royalty figures arrived after a strong run, with Genmab's share price at DKK2,130 and a 90 day share price return of 11.49%. The 1 year total shareholder return sits at 41.72%, while longer term total shareholder returns over three and five years have been negative, suggesting momentum has picked up more recently. If Genmab's news has you looking more broadly at cancer and biotech names, it could be a good moment to see what else is emerging among healthcare stocks So with Genmab trading close to
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) [Yahoo! Finance]Yahoo! Finance
- Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]Yahoo! Finance
- Genmab A/S (NASDAQ:GMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $39.00 price target on the stock.MarketBeat
- Genmab: Darzalex Growth Fuels Rally, Upside Is Tight [Seeking Alpha]Seeking Alpha
- Genmab (GMAB)'s Future Potential Underappreciated by Market [Yahoo! Finance]Yahoo! Finance